



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Ritonavir Mylan

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IB/0020/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO	09/01/2024		SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IB/0019	B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate	28/08/2023	n/a		
IAIN/0018	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	17/05/2023		SmPC and PL	
IAIN/0017	B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site	31/01/2023	n/a		
IA/0016	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	06/12/2022	n/a		
R/0015	Renewal of the marketing authorisation.	23/06/2022	22/08/2022	SmPC, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Ritonavir Mylan in the approved indication remains favourable and therefore recommended the renewal of the

					marketing authorisation with unlimited validity.
IB/0014/G	This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	05/05/2022	22/08/2022	SmPC, Labelling and PL	
T/0013	Transfer of Marketing Authorisation	24/09/2021	18/11/2021	SmPC, Labelling and PL	
IB/0012/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following	08/09/2021	18/11/2021	SmPC, Labelling and PL	

	assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IA/0011	A.7 - Administrative change - Deletion of manufacturing sites	16/02/2021	18/11/2021	Annex II and PL	
IA/0010	A.7 - Administrative change - Deletion of manufacturing sites	07/01/2021	n/a		
II/0007/G	This was an application for a group of variations. B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold	06/11/2020	21/04/2021	SmPC and PL	The SmPC sections 3, 6.3 and 6.5 have been updated as follows: 3. PHARMACEUTICAL FORM Film coated tablet (tablet). Yellow, capsule shaped, biconvex, beveled edge film coated tablet, approximately 19.1 mm x 10.2 mm, debossed with 'M163' on one side and plain blank on the other side. 6.3 Shelf-life 18 months. After first opening, use within 45 days. 6.5 Nature and contents of container HDPE bottle with polypropylene screw cap with aluminium induction sealing liner wad and a desiccant.

	compared to the originally approved batch size B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms				The Labelling and Package Leaflet have been updated accordingly.
IB/0009	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	25/03/2020	21/04/2021	SmPC and PL	
IAIN/0008	B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	26/02/2020	21/04/2021	Annex II and PL	
IB/0006/G	This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference	15/10/2019	14/11/2019	SmPC, Annex II, Labelling and PL	

	product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH				
IA/0005/G	This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer	12/06/2019	n/a		

	B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer				
N/0004	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	15/03/2019	06/05/2019	PL	
IAIN/0003	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	27/11/2018	06/05/2019	SmPC	
IB/0002	C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation	09/07/2018	06/05/2019	SmPC, Labelling and PL	
IAIN/0001	B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes	03/05/2018	06/05/2019	SmPC, Labelling and PL	